Skip to content
Human-limitedGH-releasing peptide for lean mass and recovery

Ipamorelin

Also indexed as NNC 26-0161

A selective growth hormone secretagogue and ghrelin mimetic that stimulates pituitary GH release with high specificity and minimal effect on cortisol or prolactin.

Overview

Selectively binds to ghrelin receptors (GHS-R1a) in the pituitary to stimulate GH release.

Proposed mechanism

Binds to the ghrelin receptor (GHS-R1a) in the pituitary and hypothalamus, triggering pulsatile GH release without significantly stimulating ACTH or cortisol pathways.

What the evidence supports

Human data exists but the trials are small, short-term, or not yet replicated.

Graded Human-limited

Human data that exists but is thin: open-label work, single-arm studies, small cohorts, or observational follow-up without randomisation.

Key citations

Representative primary sources, including results that did not favour the compound.

  1. [1]

    Ipamorelin: A new GH secretagogue

    · DOI:10.1210/endo.139.6.6018 · 1998

  2. [2]

    GH-releasing peptides review

    · DOI:10.1016/S0083-6729(08)60970-X · 2003

  3. [3]

    Raun et al. — Ipamorelin, a new GH-releasing peptide

    · · 0

  4. [4]

    Johansen et al. — Ipamorelin selectivity for GH release

    · · 0

Citation records in this build are illustrative placeholders for the design.

Reference information for research purposes. Not medical advice, and not a recommendation to use any compound. Many entries describe substances that are not approved for human use.

Related profiles

ACE-031

Anecdotal

ACVR2B-Fc myostatin/activin trap

ACVR2B-Fc fusion protein for myostatin & activin inhibition.

0 RCT · 0 human · 0 preclinical

growth

Adamax

Anecdotal

Nootropic peptide blend for cognition and mood

Adamax is a research peptide blend reported to combine nootropic and neuroprotective peptide components aimed at enhancing cognitive function, mood stability, and neural recovery. It is marketed primarily for its potential effects on dopaminergic and serotonergic signaling pathways. Evidence is largely limited to preclinical and anecdotal sources, with no published human clinical trials specific to the Adamax formulation.

0 RCT · 0 human · 0 preclinical

cognition

B7-33

Animal

Biased RXFP1 agonist for cardiac fibrosis

B7-33 is a single-chain peptide analog of human relaxin-2, engineered to selectively activate the RXFP1 receptor without triggering the cAMP signaling pathway. It demonstrates potent anti-fibrotic, vasodilatory, and cardioprotective effects in preclinical models. Research primarily focuses on its potential in heart failure, pulmonary arterial hypertension, and organ fibrosis.

0 RCT · 0 human · 0 preclinical

Cardiovascular